Phase I Clinical Trial of Pegylated Liposomal Doxorubicin and Docetaxel in Patients With Advanced Solid Tumors
American Journal of Clinical Oncology, 02/11/2011
Iqbal S et al. – This combination of PLD and T was found to be feasible and tolerable. The recommended dose for phase II studies is PLD 20 mg/m2 on days 1 and 15 and T 35 mg/m2 on days 1, 8, and 15.